UA-162885474-1 Jump to content
The search index is currently processing. Activity stream results may not be complete.

All Activity

This stream auto-updates     

  1. Last week
  2. For many, many years Zuckerburg has held out his company as a model of transparency. He also has been noteable for his apologies, upon apologies, for his company's failures. Tonight we now learn through the New York Times, that there were concerns brought to the attention of Zuck by internal teams which were ignored. This is a new story... Not the one brought by the whistleblower 2 weeks ago on the TV show; "60 Minutes".
  3. You should try out or another App
  4. I am totally fed up with FB and IG when it comes to the algorithm's ability to decide who should and shouldn't be erased. I am fed up.
  5. Earlier
  6. We keep hearing that our Members' favorite social media sites are NOT effective at fostering collaboration, let alone guiding good solid consumer, or business, discussions. Do you agree? One case that has been brought to our attention, is Facebook. Many people who made the mistake in associating the keyword, "cannabis", with their business are being castigated by Facebook. How you ask? The answer is that they're not allowed to post any ads, whatsoever! That's an outrage. Especially when the castigated individuals have no recourse to correct Facebook's false assumptions. So, in one case a business selling horticultural supplies such as grow tents, LED lights, plant nutrients, etc. was completely shut down by Facebook and Instagram. The business was not even allowed to file a complaint regarding their true business intent, which was all quite legal, or with the Facebook policy, Itself. There are thousands of people and businesses which have been derailed by this major mismanagement policy fuck-up! No wonder people want these 2 behemoths broken up. YouTube might be another social media site which presents problems? But from what we can tell... they have a much better track record in correcting ad issues, than Facebook and Instagram. But, YouTube has been designed to present videos, not to foster discussion forums or aggregate C+H knowledge, per se. So what alternative social media sites are left? The real question does not need to be focused solely at ad issues. It should focus on whether sites like LinkedIn or TicToc, or Twitter enable you to get involved, or start, a Special Interest Group (SIG) or a Birds-of-a-Feather (BOF) group? They Don't. That's how the Global Associations of C+H Value Chain Organizations came about. We want to support consumer and business SIGs. We want to foster collaboration... not prevent it! Let us know how your favorite social media site is helping you, or your business, or hindering you?
  7. MemberSupport

    What is Kief?

    Kief, sometimes transliterated as keef, also known as ‘’Dust’’ and "Chief" a.k.a cannabis crystals among other names, refers to the most pure and cleanest, collection of loose resin trichomes cannabis that may accumulate by being sifted from cannabis infructescences (i.e. the fruiting heads of the plant flowers and buds) with a mesh screen or sieve.
  8. MemberSupport

    What is hashish?

    Hashish, also known as hash, is a drug made by compressing and processing trichomes of the cannabis plant. It is consumed by smoking, typically in a pipe, bong, vaporizer or joint, or via oral ingestion. Hash has a long history of usage in countries such as Pakistan, Afghanistan, India, Iran, Morocco, and Lebanon.
  9. We have had an historic herbal farm for quite some time. We've raised, harvested, dried and marketed a ton of both edible and decorative herbs (no cannabis, nor hemp). We want to start this discussion thread to stoke our members' interests in chatting about the wide variety of essential oils and the many applications that they can provide for wellness, domestic uses, etc.. Have at it!
  10. If your team is interested in building a corporate charter for pursuing Value Chain Management (VCM) open standards, best practices and processes, then you have come to the right place! We use the VCM charter to address Phase 1 shown in the first diagram below. That's where a Value Chain Management charter team moves their company from an "Unconscious Incompetent state" to a "Conscious Incompetent state". In other words, the VCM charter consists of a mandate by corporate executives as Sponsors who understand why Value Chain Management open standards, best practices and processes all contribute towards the creation of significant Strategic Shareholder Value in order to generate 1.) a "burning platform for business change" so that the company can 2.) build a sustainable competitive advantage while 3.) generating above average operational performance and financial returns. Next, the VCM Charter document is produced and it may include a rudimentary GAP Assessment. The VCM Charter is then used to sell the need to conduct a VCM Strategic Value Assessment (SVA). The SVA will inform the company on the level of hard and soft benefits to anticipate when one or more VCM projects are completed. We can help you to get through these stages quickly and help you to target those areas of VCM which will help you the most!
  11. If your company is able to answer these mission-critical questions pertaining to strategic shareholder value creation, then you may NOT need our Association's guidance on Value Chain Management "open standards", best practices and processes... 1.) Product Investments - What is the correct approach for making Product Investment Decisions? Should they be made on a business profitability basis or on a product profitability basis, and Why? 2.) Capacity Investments - What is the correct approach for making Capacity Investment Decisions? Should they be made on a workflow management basis or on a resource utilization basis and Why? 3.) Factory Improvement Investments - What is the correct approach for making Factory Improvement Investment Decisions? Should they be made on a factory throughput basis or on a cost savings basis and Why?
  12. Exploring the Effects of Light and Air It is a well-known fact that cannabis needs light and airflow to grow, but what about after it's been harvested and cured? What happens when that eighth of flower sits on a dispensary shelf for six months or a year? Most cannabis products available in dispensaries today usually have an expiration date on the label, but why? Does it go bad? Why are we told to keep our cannabis flower away from the light? Let’s dive right in and explore the science behind air and light and what it does to our cannabis flower. What Science Has Found A few studies have been conducted regarding the stability or shelf life of THC and have helped shed some light on how cannabis should be packaged and stored. The scientific community first became aware of light degrading THC because of a study conducted in 1971. The study concluded that; to best preserve THC, cannabis should be stored in nitrogen instead of oxygen and away from ultraviolet light. In 1976, another study determined that exposure to light (not direct sunlight) was the number one factor in cannabinoid loss over time. This study also showed that THC loss from light exposure does not lead to an increase in the cannabinoid CBN or cannabinol, but rather air oxidation in dark conditions does. A more recent study at the University of Mississippi in 1999 showed that over one year, THC levels in cannabis samples stored in a dark vault reduced by 16.6% of their original amount and as much as 41.4% after four years. Scientists found that; at an average loss rate of 1.3% per month, most cannabis smoked within one year of being harvested should be relatively close to ideal freshness if kept under proper conditions. So, What Does All That Mean? The two main takeaways from these studies are that THC will do one of two things when it degrades. Exposure to oxygen in dark conditions will turn THC into CBN over time, but exposure to ultraviolet light can simply destroy THC. So, what does that mean for the stash of bud you lost two years ago, or the cannabis sitting on dispensary shelves in clear jars, or how about that bud that just endured a two-hour-long photoshoot for High Times? If you happen to find that old stash of bud from last 4/20 buried deep in your sock drawer, go ahead and smoke it, but be prepared to take a nap! In those dark conditions, the THC will be broken down into CBN and be apparent from the clear-milky trichomes turning a dark amber color. While the effects of CBN are still being studied, Steep Hill Labs has said that 5mg of CBN is equal to 10mg of Valium, and therefore if you smoke cannabis left in a drawer for an extended length of time, it may make you feel more tired than it would otherwise. But What About My Camera Flash and Display Lights? There have been studies conducted on the effects of fluorescent light and flash photography on works of art, but not many regarding the effect it has on cannabis. From the studies conducted on THC stability, we can assume that too much exposure to high-intensity light will affect the stability of THC. Most light humans can see with the naked eye is classified as non-ionizing radiation on the electromagnetic spectrum and is therefore harmless to humans and cannabis. Ultraviolet or UV light is right on the line of ionizing and non-ionizing, and most compact fluorescent lamps or CFL bulbs produced today emit a small amount of UV light. When it comes to modern camera flashes and LED display lights, the jury is still debating on how it can affect cannabis. If you're displaying your top-shelf bud under bright LED lights for days on end, there will most likely be some loss of THC. On the other hand, a few minutes or even an hour of exposure to camera flashes or bright LED display lights probably won’t affect the potency of your cannabis too much. Personal Research Being a cannabis connoisseur and a science fanatic, I decided to do some research on this. I regularly review cannabis, which involves taking quite a few pictures of it under magnification and about an hour of exposure to bright LED lights. I started paying attention to the trichomes and how they look because that can indicate THC degradation. I even left a bud under a MasonBrite stash jar for thirty minutes straight and didn’t notice any change in the appearance of the trichomes or potency compared to the rest of the batch. Another bud, I left under a heat lamp for a week, and there was a visible difference in the trichomes and the effects I felt afterward; the trichomes were dark amber, and I slept like a baby. So, what is the Verdict? The three things that can affect the potency and quality of cannabis are oxygen, heat, and light. Overexposure to heat or UV light will eventually degrade the THC to lower amounts, but don’t worry; showing off your prized bud under some LED lights for a few minutes to your friends here and there won't do any significant damage. It is a good idea to keep your cannabis out of direct sunlight, away from any heat sources, and in a sealed container. If you are someone that thoroughly inspects their cannabis before you smoke - twenty minutes under an LED light will not ruin your stash - just make sure that you don’t leave the light on and forget about it. Through all of the cannabis reviews and research that I have done, it is apparent that most cannabis connoisseurs will most likely smoke their stash long before it ever starts to lose its potency unless you leave it in the sun for a week. This article was written by Adam Merkle, Founder of Let's Enjoy Cannabis. To view more unique content by him, please go here. References: 1971 Study: 1976 Study: 1999 Study:
  13. Our three Associations (International, Canadian and American) are announcing a new industry benchmarking Sponsored Service for C+H member firms. The Break-Point Software-as-Service (SaaS) offering is geared towards providing the Sponsor with a detailed assessment of a portion of their value chain. Then, the Sponsor can not only use the benchmarking system internally, but they can also sponsor an industry benchmarking system capability for peer companies, which allows the firm to share benchmarking measures, anonymously. There are several BreakPoint Value Chain Management Sponsorship opportunities for each of these industry benchmarking areas for Cannabis and Hemp (C+H) member firms sharing a similar NAICS classification. They are as follows: 1. Value Chain Management End-To-End Benchmarking 2. New Drug Discovery Benchmarking (Design Chain) 3. New CPG Product Introduction Benchmarking (Design Chain) 4. Brand Visibility and Mindshare Benchmarking 5. Quality Management System (QMS) Benchmarking 6. ERP System Benchmarking 7. Supply Chain Benchmarking 8. Operational Risk Reporting and Loss Management Benchmarking 9. Indoor / Outdoor Cultivation Benchmarking 10. Internal / External Audit Benchmarking 11. Other Benchmarking Areas are under consideration The reason why competitors want to benchmark against their peers is simple... it allows the employees and shareholders and executive management to self-assess their enterprise performance by using "Peer Average" and "Best-in-Class" (BIC) datapoints for any Key Performance Indicators (KPI's) which the Sponsor or Sponsors would like to benchmark against. This is the proven and safe way to drive significant shareholder value by implementing proven processes, practices, Key Performance Indicators (KPI's), Key Risk Indicators (KRI's) and a whole lot more!
  14. Did you see the latest Nova TV show on Cannabis? What did you think?
  15. MemberSupport

    The FDA and Cannabis

    The FDA understands that there is increasing interest in the potential utility of cannabis for a variety of medical conditions, as well as research on the potential adverse health effects from use of cannabis. To date, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. The agency has, however, approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These approved drug products are only available with a prescription from a licensed healthcare provider. Importantly, the FDA has not approved any other cannabis, cannabis-derived, or cannabidiol (CBD) products currently available on the market. CANNABIS Cannabis sativa L. is a plant that contains over 80 different naturally occurring compounds called “cannabinoids” Two well-known cannabinoids: Cannabidiol (CBD) Tetrahydrocannabinol (THC) Plants are grown to produce varying concentrations of cannabinoids – THC or CBD These plant variations are called cultivars Cannabis-derived compounds Compounds occurring naturally in the plant – like CBD and THC These compounds are extracted directly from the plant Can be used to manufacture drug products Example: highly-purified CBD extracted from the plant Cannabis-related compounds These synthetic compounds are created in a laboratory Can be used to manufacture drug products Some synthetic compounds may also occur naturally in the plant and some may not Examples: synthetically-derived dronabinol (also naturally occurring) and nabilone (not naturally occurring) FDA has approved Epidiolex, which contains a purified form of the drug substance cannabidiol (CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. That means FDA has concluded that this particular drug product is safe and effective for its intended use. The agency also has approved Marinol and Syndros for therapeutic uses in the United States, including for nausea associated with cancer chemotherapy and for the treatment of anorexia associated with weight loss in AIDS patients. Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9- tetrahydrocannabinol (THC) which is considered the psychoactive intoxicating component of cannabis (i.e., the component responsible for the “high” people may experience from using cannabis). Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to THC and is synthetically derived. Cesamet, like dronabinol-containing products, is indicated for nausea associated with cancer chemotherapy. FDA is aware that unapproved cannabis and/or unapproved cannabis-derived products are being used to treat a number of medical conditions including, AIDS wasting, epilepsy, neuropathic pain, spasticity associated with multiple sclerosis, and cancer and chemotherapy-induced nausea. Caregivers and patients can be confident that FDA-approved drugs have been carefully evaluated for safety, efficacy, and quality, and are monitored by the FDA once they are on the market. However, the use of unapproved cannabis and cannabis-derived products can have unpredictable and unintended consequences, including serious safety risks. Also, there has been no FDA review of data from rigorous clinical trials to support that these unapproved products are safe and efficacious for the various therapeutic uses for which they are being used. FDA understands the need to develop therapies for patients with unmet medical needs, and does everything it can to facilitate this process. FDA has programs such as Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review that are designed to facilitate the development of and expedite the approval of drug products. In addition, the FDA’s expanded access (sometimes called “compassionate use”) statutory and regulatory provisions are designed to facilitate the availability of investigational products to patients with serious diseases or conditions when there is no comparable or satisfactory alternative therapy available, either because the patients have exhausted treatment with or are intolerant of approved therapies, or when the patients are not eligible for an ongoing clinical trial. Through these programs and the drug approval process, FDA supports sound, scientifically-based research into the medicinal uses of drug products containing cannabis or cannabis-derived compounds and will continue to work with companies interested in bringing safe, effective, and quality products to market.
  16. The National Organization of the Reform of Marijuana Laws (NORML) reports that... "Cannabinoids have a relatively unique safety record, particularly when compared to other therapeutically active substances. Most significantly, the consumption of cannabinoids — regardless of quantity or potency — cannot induce a fatal overdose because, unlike alcohol or opiates, they do not act as central nervous system depressants. According to a 1995 review prepared for the World Health Organization, “There are no recorded cases of overdose fatalities attributed to cannabis, and the estimated lethal dose for humans extrapolated from animal studies is so high that it cannot be achieved by … users.” "Cannabinoids also appear to be largely non-toxic to healthy cells and organs" writes Dr. Mitch Earleywine in the 2002 Oxford University Press publication, Understanding Marijuana: A New Look at the Scientific Evidence, “Cannabis is essentially non-toxic.” "A systematic review of clinical trials over a 40-year period, published in the Canadian Medical Association Journal, found no higher incidence of serious adverse effects from cannabis-consuming subjects compared to controls, and cited ‘dizziness’ as the primary reported non-serious adverse event reported. Additionally, in some initial trials, cannabinoids have demonstrated neuroprotective properties against toxic agents and have shown profound anti-cancer properties. Stated the National Academy of Sciences, Institute of Medicine in their 1999 review, Marijuana and Medicine: Assessing the Science Base, “Except for the harms associated with smoking, the adverse effects of marijuana use are within the range of effects tolerated for other medications.” A more recent meta-analysis assessing the effects of long-term exposure to cannabis concludes, “Overall, by comparison with other drugs used mainly for ‘recreational’ purposes, cannabis could be rated to be a relatively safe drug.” Nonetheless, cannabis should not necessarily be viewed as a ‘harmless’ substance. Consuming cannabis will alter mood, influence emotions, and temporarily alter perception, so consumers are best advised to pay particular attention to their set (emotional state) and setting (environment) prior to using it. It should not be consumed immediately prior to driving or prior to engaging in tasks that require certain learning skills, such as the retention of new information. Further, there may be some populations that are susceptible to increased risks from the use of cannabis, such as adolescents, pregnant or nursing mothers, and patients with or who have a family history of mental illness. Patients with hepatitis C, decreased lung function (such as chronic obstructive pulmonary disease), or who have a history of heart disease or stroke may also be at a greater risk of experiencing certain adverse side effects from cannabis. As with any therapy, patients concerned about such risks should consult thoroughly with their physician before deciding whether the medical use of cannabis is safe and appropriate for them.
  17. By Paul Armentano of NORML. Scientists have only recently begun to discover the answer to this question as researchers today are just beginning to understand the many complex ways that cannabinoids interact with the human body. Subjects experience psychological and physiological effects after ingesting cannabis because cannabinoids, THC in particular, interact with a complex and dense receptor system within the body. The CB1 receptors, first identified in the late 1980s, reside predominantly in the nervous system and their stimulation is responsible for the plant’s psychoactive and behavioral effects, among other functions. The CB2 receptors, identified in the early 1990s, reside primarily in the immune system and are involved in the moderation of a number of biological functions, including inflammation and pain response. Naturally occurring chemicals in human body (so-called endocannabinoids), which possess a similar molecular structure to herbal cannabinoids, act as neuromodulators and cytokine modulators within this receptor system to regulate many of the body’s essential physiological functions — including appetite, blood pressure, reproduction, bone growth, tumor modulation, immunity, inflammation, pain sensation, memory, and muscle tone, among others. It is theorized that a properly functioning endogenous cannabinoid receptor system is necessary for good health and that certain disease types may be the result of deficiencies within this system.
  18. By Paul Armentano of NORML. Historically, humans have used various parts of the cannabis plant for a multitude of purposes. Most people today are readily aware that cannabis is consumed socially as a mood-enhancer. By contrast, certain varieties of cannabis – as well as most parts of the plant, including the seeds and the stalk – contain virtually no psychoactive properties but may be utilized in other ways. For example, ground seeds from the cannabis plant contain high and balanced levels of essential amino acids and essential fatty acids and may be baked into a variety of nutritional food-stuffs, such as bread, butter, and salad dressing. Oil can also be processed from cannabis seeds and used for sautéing or consumed as a nutritional supplement.[4] Since the seeds contain negligible amounts of the plant’s primary psychoactive agent, the importation and domestic sale of certain cannabis-based foods, oils, and sterilized seeds is permitted in the United States under federal law. The stalk of the marijuana plant, primarily of the cannabis sativa variety – which can grow as high as 20 feet in height – can also be harvested for best fiber content. This renewable resource is a common source of paper, rope, and clothing. Most industrialized nations, including Canada, Japan, Australia, and the European Union, regulate the commercial production of low THC varieties of cannabis for industrial purposes.[5] During World War II the U.S. government commissioned tens of thousands of domestic farmers to grow cannabis to assist with America’s wartime needs. Following the War’s conclusion, however, the United State’s government imposed a complete ban on the domestic production of the plant, including the cultivation of non-psychoactive cannabis sativa varieties. That ban continues today. The plant’s cannabinoids are largely responsible for cannabis’ physiological, mood-altering, and therapeutic effects. THC, the most studied of all the plant’s cannabinoids, is psychoactive and is primarily responsible for the plant’s influence on mood and behavior. It also possesses various therapeutic effects. Most acknowledged among these are pain relief, appetite stimulation, nausea and vomiting mitigation, anti-spasticity and anti-spasmodic effects, and intraocular pressure reduction in patients with glaucoma. An isolated stereoisomer of THC is presently available as an FDA-approved product Dronabinol, which is classified under federal law as a Schedule III substance. It is FDA-approved as an appetite stimulant and as an anti-emetic in patients with HIV/AIDS or undergoing chemotherapy treatment. A number of additional, non-psychotropic cannabinoids such as CBD also possess numerous therapeutic properties. To learn more, please see a summary of many of these cannabinoids and their potential therapeutic applications.
  19. The term ‘marijuana’ (sometimes spelled ‘marihuana’) is Mexican in origin and typically refers to any part of — or any one of — the three distinctive subspecies of the cannabis plant: 1.) Cannabis sativa (which tends to grow tall and stalky) 2.) Cannabis indica (which tends to grow smaller and bushier) 3.) Cannabis ruderalis (found primarily in Russia and Eastern Europe.) Grown outdoors, the cannabis plant typically achieves maturity within three to five months. Cultivated indoors under optimum heat and lighting, the plant may reach maturity within as few as 60 days. Despite almost a century of federal, criminal prohibition, an estimated one in seven US adults acknowledge being current marijuana consumers.
  20. Sponsor; The International Association of C+H Value Chain Organizations Sea change or sea-change is an English idiomatic expression which denotes a substantial change in perspective, especially one which affects a group or society at large, on a particular issue. This term is quite appropriate when it comes to C+H new drug discovery efforts. The average period to develop a new drug application is 10 - 12 years. Industry leaders are now trying to half this time-to-market. This feat will vastly change our Time-To-Market and Time-To-Volume norms. But how are we to accomplish this? The answer: Graph knowledge bases and massively parallel processing can be used by progressive organizations to support Value Chain information flows as well as tackling both OLAP and OLTP (On-Line Analytical Processing and On-Line Transaction Processing. Here's why... One Value Chain Management technical data engineering aspect is the use of Knowledge Graph databases to address digital transformations of highly complex data using both graph and massively parallel processing. Here's why Time-To-Market and Time-To-Volume are so important in the New Drug Discovery realm...
  21. As you may have known, Cannabis strains vary widely. Some may induce sleep, put you in a creative mood or provide you with the feeling that you can take on even the most massive of "To-Do" lists. This discussion thread focuses on the top strains which promote feelings of a need to accomplish stuff, be productive, have the energy to tackle some to-do items, today! Have you tried any of these 3 Strains? What did you think? Feel? Chocolope Feminized Green Crack Jack Herer We'd like to hear any of your opinions regarding one or more of these 3 well-known strains.
  22. MemberSupport

    CEO Pictorial.PNG

  23. MemberSupport

    Dabbing; What is it?

    Dabbing refers to the process of heating a concentrate on a hot surface and then inhaling it through what is known as a dab rig. Dabbing is a very popular way of consuming concentrates as it produces an intense high. Although it depends upon the type of dab that you are consuming, whether it be oil or shatter, typically dabbing is more potent. Because of this, people that have chronic pain or other medical issues often prefer to consume concentrates in the form of dabs. Before you actually try, dabbing... you need to read this... Cannabis Concentrates; The Complete Guide It's well worth it!
  24. Are there any specific Pre-Rolls strains that you would recommend, NOT buying? I'd love to know where you made the purchase (general part of the country) and why? Of course, We're also interested in positive, memorable pre-roll purchases, too!
  25. MemberSupport


  26. MemberSupport


  1. Load more activity
  • Create New...

Important Information

(terms) (privacy) (guidelines) (cookies)